Screening for Intestinal Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Critically Ill Patients: Expected Benefits and Evidence-based Controversies.
Anti-Bacterial Agents
/ pharmacology
Carbapenem-Resistant Enterobacteriaceae
/ drug effects
Carrier State
Critical Illness
Cross Infection
/ epidemiology
Enterobacteriaceae Infections
/ drug therapy
Evidence-Based Medicine
Humans
Intestinal Mucosa
/ microbiology
Microbial Sensitivity Tests
Population Surveillance
beta-Lactamases
/ genetics
carbapenem
contact precautions
critical care
extended-spectrum beta-lactamase
ventilator-associated pneumonia
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
30 05 2019
30 05 2019
Historique:
received:
06
08
2018
accepted:
04
10
2018
pubmed:
13
10
2018
medline:
29
7
2020
entrez:
13
10
2018
Statut:
ppublish
Résumé
The rising burden of intensive care unit (ICU)-acquired infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) strengthens the requirement for efficient prevention strategies. The detection of intestinal carriage of ESBL-E through active surveillance cultures (ASC) and the implementation of contact precautions (CP) in carriers are currently advocated in most high-income countries, to prevent cross-transmission and subsequent ESBL-E infections in critically-ill patients. Yet, recent studies have challenged the benefit of ASC and CP in controlling the spread of ESBL-E in ICUs with high compliance to standard hygiene precautions and no ongoing outbreak of ESBL-producing Klebsiella pneumoniae or Enterobacter spp. Besides, given their debated performance to positively predict which patients are at risk of ESBL-E infections, ASC results appear of limited value to rationalize the empirical use of carbapenems in the ICU, emphasizing the urgent need for novel anticipatory and diagnostic approaches. This Viewpoint article summarizes the available evidence on these issues.
Identifiants
pubmed: 30312366
pii: 5127161
doi: 10.1093/cid/ciy864
doi:
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2125-2130Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.